AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 222 min read$MEDP

Medpace Q3 Earnings Call Highlights

Medpace reported a 10.6% year-over-year increase in net new business awards to $873.4 million in Q3, with a total 12-month backlog of $3.02 billion. Ending backlog was $3.2 billion, up 5.6% year-over-year. The company expects $1.99 billion of backlog to convert into revenue over the next year. Management noted shifts in therapeutic mix and strong pending opportunities. Medpace plans to provide 2027 guidance in February, with fourth-quarter awards and cancellations influencing the outlook.

Original reporting
finance.yahoo.com
Published Oct 22, 2026, 3:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 3:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Medpace Q3 Earnings Call Highlights — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$MEDPBullishMed
01

Why it matters

The earnings beat and strong backlog are likely to support a short-term price rally, though margin pressure from upcoming expansion could temper upside.

02

Market read

Earnings release provides fresh data for traders; potential catalyst for short-term price movement.

03

What to watch

The $20M cost headwind from the Cincinnati campus could pressure margins in 2027.

Relevance 7/10Novelty 8/10Timing: post-market today

Background

Medpace (NASDAQ:MEDP) reported Q3 results with higher than expected awards and cash flow, and announced a new $1B share repurchase program.

Company-level read

Ticker impact

$MEDPBullishHigh confidence
Context

Q3 earnings call disclosed $873.4M new awards, 5.6% backlog growth and $216.6M operating cash flow, plus a $1B share repurchase authorization.

Expected impact

likely modest upside as market prices in stronger backlog and cash flow

Evidence & confidence

New earnings numbers and guidance are fresh primary data; investors may bid the stock higher.

Market effects

Sector

CRO sector may see renewed interest from investors tracking biotech outsourcing spend.

Regional

U.S. biotech services market could benefit from higher award volumes.

Global

Limited to Medpace and peers; no broad macro effect.

Counterpoint

What could challenge this read

Backlog growth may be offset by higher operating costs from campus expansion and potential cancellations.

Key entities

  • Company
    Medpace Holdings, Inc.

    Contract research organization providing clinical development services.

Read at source← All news

StoryMedpace Reports Q3 Earnings Beat and Authorizes $1 Billion Buyback

Also covered by

4 outlets

Related articles

OCT 23
$MEDPMedAI 8/10

MEDP Q3 deep dive: bookings strength drives growth, margin expansion continues

MEDP reported Q3 revenue of $716M, beating estimates, with EPS of $4.84 and adjusted EBITDA of $172.1M. The company reconfirmed full-year revenue guidance of $2.85B and raised EPS guidance to $18.15. Growth was driven by strong bookings in oncology research and margin expansion from a favorable project mix. Management highlighted stable competition, low turnover, and sustained bookings momentum, but noted project cancellations as a watchpoint.

finance.yahoo.com2 min
OCT 22
$MEDPMedAI 8/10

Medpace 3Q 2026: Revenue $716M, EPS $4.84— 10-Q Summary

Medpace Holdings reported Q3 2026 revenue of $716M, up 8.5% YoY, with net income rising 23.7% to $137.46M and EPS increasing 25.4% to $4.84. Growth was driven by Metabolic, Oncology, and CNS services. Nine-month revenue grew 16.9%, net awards reached $873.4M, and backlog increased 5.6% YoY to $3.17B. The company plans organic growth and selective acquisitions.

tradingview.com2 min
OCT 22
$MEDPHighAI 8/10

Medpace (MEDP) Q3 2026 Earnings Call Transcript

Medpace (MEDP) reported Q3 2026 revenue of $716M, up 8.5% YoY, with EBITDA of $172.1M (up 16%) and net income of $137.5M (up 23.7%). Guidance raised: revenue $2.835B-$2.855B (12-12.8% growth), EBITDA $638M-$652M (14.4-16.9% growth), EPS $17.97-$18.32. Board approved $1B share repurchase program. Net new business awards up 10.6% QoQ.

finance.yahoo.com2 min
OCT 22
$MEDPHighAI 8/10

Medpace Q3 2026 slides: record awards fuel profit beat, guidance raised

Medpace Holdings (NASDAQ:MEDP) reported Q3 2026 revenue of $716.0M, up 8.5% YoY, and adjusted earnings of $4.84 per share, exceeding estimates. Net income rose 23.7% to $137.5M, with EBITDA margin widening to 24.0%. The company raised its full-year guidance, citing record new business awards and strong profitability trends. Shares traded near $659.37, close to their 52-week high.

investing.com2 min
OCT 22
$MEDPHighAI 8/10

Why is Medpace stock sliding today?

Medpace Holdings Inc (MEDP) fell 1.6% in after-hours trading after its Q3 2026 earnings report. Adjusted EPS of $4.84 beat estimates, but full-year revenue guidance of $2.835B-$2.855B missed expectations. The board replaced a $527M stock buyback program with a $1B program. Insiders sold $467M in shares over the past year. The S&P 500, Dow Jones, and NASDAQ also declined during regular trading.

investing.com2 min